Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals
| Autor: | Vladmir Cláudio Cordeiro de Lima, André Henrique Crepaldi, Adriana Helena Moreira, José Vassallo, Marcia Torresan Delamain, Fernando Augusto Soares, Guilherme Rossi Assis-Mendonça, Carmino Antonio De Souza, Felipe D'Almeida Costa |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty Follicular lymphoma Histopathology 03 medical and health sciences 0302 clinical medicine Chemoimmunotherapy Prednisone Internal medicine hemic and lymphatic diseases Hemotherapy Immunology and Allergy Medicine Hematology Mantle cell lymphoma business.industry lcsh:RC633-647.5 Cancer lcsh:Diseases of the blood and blood-forming organs medicine.disease Prognosis 030220 oncology & carcinogenesis Rituximab Original Article business 030215 immunology medicine.drug |
| Zdroj: | Hematology, Transfusion and Cell Therapy, Vol 40, Iss 4, Pp 343-353 (2018) Hematology, Transfusion and Cell Therapy Hematology, Transfusion and Cell Therapy, Volume: 40, Issue: 4, Pages: 343-353, Published: OCT 2018 |
| ISSN: | 2531-1379 |
| Popis: | Objective: Follicular and mantle cell lymphoma are low-grade B-cell malignancies that lack good responses to chemoimmunotherapy. This study aimed to assess retrospectively clinicopathological features and to determine independent prognostic factors for follicular and mantle cell lymphoma patients treated at two Brazilian medical centers: the Hematology and Hemotherapy Center of the Universidade Estadual de Campinas (Unicamp), a public university hospital, and AC. Camargo Cancer Center, a specialized cancer center. Methods: Two hundred and twenty-seven follicular and 112 mantle cell lymphoma cases were diagnosed between 1999 and 2016. Archived paraffin blocks were retrieved and reviewed. Corresponding demographics and clinical data were recovered from medical charts. Outcome analyses considered both overall and event-free survival. Results: For follicular lymphoma treated with the R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) and R-CVP (rituximab, cyclophosphamide, vincristine sulfate, prednisone) regimens, both B-symptoms (p-value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|